Oscar Delgado – General Manager MEA, Bristol Myers Squibb

28.05.2021
Bristol Myers Squibb’s General Manager for the Middle East and Africa (MEA) Oscar Delgado outlines the company’s pandemic journey, the big changes transforming the Saudi market, the challenges on regulatory data protection, and the opportunities to make Saudi Arabia a leader in clinical trials and innovation within the region.  
Bristol Myers Squibb has lent its full support to Saudi Arabia’s 2030 Strategic Vision, and we are happy to see that the pharma industry has been recognized as a key industry for the future of its economy
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Saudi Arabia, BMS, MEA, Strategy, Access

Related Interviews

Mohamed Mazen Batterjee – Managing Director, Batterjee Pharma

Mohamed Mazen Batterjee, managing director of Batterjee Pharma, explains how he has turned the business around since joining in 2014, the interplay between the firm’s contract and proprietary manufacturing operations,…

Mohamed Mostafa – Vice President and General Manager Saudi Arabia &…

IQVIA Vice President and General Manager Saudi Arabia & Egypt Mohamed Mostafa gives his expert insights into the transformation of the Saudi pharma market in recent years, covering everything from…

Rami Rajab – Chairman, Mecomed

Mecomed is the largest medical devices, imaging, and diagnostics trade association in the Middle East and Africa (MEA). Rami Rajab, chairman, highlights the role of the association in shaping the…

Related Articles

Company Spotlight / Saudi Chemical Company Holding: At the Forefront of Saudi Healthcare’s Evolution

Saudi Chemical Company Holding (SCCH), Saudi Arabia’s leading manufacturer of civil and military explosives, has been expanding its pharma sector footprint in recent years. Today, the company has capabilities across…

Pharma Faces / Mohammed Nasser, Amgen MEA

Seasoned executive Mohamed Nasser currently oversees 16 markets for Amgen across the MEA region, including its most important – Saudi Arabia. He shares some of the key skills that pharma…

Saudi Arabia / IP: Room for Improvement?

While Saudi Arabia is becoming an increasingly attractive investment destination for global pharma, some stakeholders continue to have concerns about whether the country’s intellectual property (IP) protection system is truly…

Latest Report

Turkey Pharma Report 2021

Related Content

Saudi Arabia
BMS
MEA
Strategy
Access